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Studies have found that diabetes and thyroid disorders tend to coexist in patients. Both conditions involve a dysfunction of
the endocrine system. Thyroid disorders can have a major impact on glucose control, and untreated thyroid disorders aﬀect
the management of diabetes in patients. Consequently, a systematic approach to thyroid testing in patients with diabetes is
recommended.
1.Introduction
Thyroid diseases and diabetes mellitus are the two most
common endocrine disorders encountered in clinical prac-
tice. Diabetes and thyroid disorders have been shown to
mutually inﬂuence each other and associations between
both conditions have long been reported [1, 2]. On one
hand, thyroid hormones contribute to the regulation of
carbohydrate metabolism and pancreatic function, and on
the other hand, diabetes aﬀects thyroid function tests to
variable extents. This paper demonstrates the importance
of recognition of this interdependent relationship between
thyroid disease and diabetes which in turn will help guide
cliniciansontheoptimalscreeningandmanagementofthese
conditions.
2. Frequencyof Thyroid Disorders in
the General Population and in Patients
withDiabetes
Thyroid disorders are widely common with variable preva-
lence among the diﬀerent populations. Data from the
Whickham survey conducted in the late 1970s in the
north of England revealed a prevalence of 6.6% of thyroid
dysfunction in the adult general population [3]. In the
Colorado Thyroid Disease Prevalence study involving 25,862
participants attending a state health fair, 9.5% of the studied
population were found to have an elevated TSH, while
2.2% had a low TSH [4]. In the NHANES III study, a
survey of 17,353 subjects representing the US population,
hypothyroidism was found in 4.6% and hyperthyroidism in
1.3% of subjects [5]. The latter further observed an increased
frequency of thyroid dysfunction with advancing age and a
higher prevalence of thyroid disease in women compared to
men and in diabetic subjects compared to nondiabetic.
Several reports documented a higher than normal preva-
lence of thyroid dysfunction in the diabetic population.
Particularly, Perros et al. demonstrated an overall prevalence
of 13.4% of thyroid diseases in diabetics with the highest
prevalence in type 1 female diabetics (31.4%) and lowest
prevalence in type 2 male diabetics (6.9%) [6]. Recently,
a prevalence of 12.3% was reported among Greek diabetic
patients [7] and 16% of Saudi patients with type 2 diabetes
were found to have thyroid dysfunction [8]. In Jordan,
a study reported that thyroid dysfunction was present in
12.5% of type 2 diabetic patients [9]. However, thyroid
disorders were found to be more common in subjects with
type 1 diabetes compared to those with type 2 diabetes.
Additionally, a 3.5-fold increased risk of autoimmune thy-
roiditis was noticed in GADA positive patients [10]. Thyroid
disorders remain the most frequent autoimmune disorders
associated with type 1 diabetes. This was shown in a cross-
sectional study involving 1419 children with type 1 diabetes
mellitus, where 3.5% had Hashimoto’s thyroiditis [11]. In
addition, positive TPO antibodies have been reported in
as high as 38% of diabetic individuals and have been2 Journal of Thyroid Research
shown to be predictive for the development of clinical and
subclinical hypothyroidism [12–14]. Very recently, Ghawil
et al. documented that 23.4% of type 1 diabetic Libyan
subjects had positive TPO antibodies and 7% had positive
TG antibodies [15]. The association between AITD and
T1DMhasbeenrecognizedasavariantofAPS3referredtoas
APS3 variant [16]. Common susceptibility genes have been
acknowledgedtoconferariskfordevelopmentofbothAITD
and type 1 diabetes mellitus. Currently, at least four shared
genes have been identiﬁed including HLA [17–22], CTLA-4
[23], PTPN22 [24, 25], and FOXP3 genes [26].
3. Effects of Thyroid Hormones on
Glucose Homeostasis
Thyroid hormones aﬀect glucose metabolism via several
mechanisms. Hyperthyroidism has long been recognized to
promote hyperglycemia [27]. During hyperthyroidism, the
half-life of insulin is reduced most likely secondary to an
increased rate of degradation and an enhanced release of
biologically inactive insulin precursors [28, 29].
In untreated Graves’ disease, increased proinsulin levels
in response to a meal were observed in a study by Bech et al.
[30]. In addition, untreated hyperthyroidism was associated
with a reduced C-peptide to proinsulin ratio suggesting an
underlying defect in proinsulin processing [31]. Another
mechanism explaining the relationship between hyperthy-
roidism and hyperglycemia is the increase in glucose gut
absorption mediated by the excess thyroid hormones [32,
33].
Endogenous production of glucose is also enhanced in
hyperthyroidismvia severalmechanisms. Thyroidhormones
produce an increase in the hepatocyte plasma membrane
concentrations of GLUT2 which is the main glucose trans-
porter in the liver, and consequently, the increased levels of
GLUT-2 contribute to the increased hepatic glucose output
and abnormal glucose metabolism [34, 35]. Additionally,
increased lipolysis is observed in hyperthyroidism resulting
in an increase in FFA that stimulates hepatic gluconeogene-
sis. The increased release of FFA could partially be explained
by an enhanced catecholamine-stimulated lipolysis induced
by the excess thyroid hormones [36]. Moreover, the nonox-
idative glucose disposal in hyperthyroidism is enhanced
resulting in an overproduction of lactate that enters the Cori
cycle and promotes further hepatic gluconeogenesis. The
increaseinGH,glucagonandcatecholaminelevelsassociated
with hyperthyroidism further contributes to the impaired
glucose tolerance [37–39].
It is well known that diabetic patients with hyper-
thyroidism experience worsening of their glycemic control
and thyrotoxicosis has been shown to precipitate diabetic
ketoacidosis in subjects with diabetes [40, 41].
As for hypothyroidism, glucose metabolism is aﬀected as
well via several mechanisms. A reduced rate of liver glucose
production is observed in hypothyroidism [42]a n da c c o u n t s
for the decrease in insulin requirement in hypothyroid
diabetic patients. Recurrent hypoglycemic episodes are the
presenting signs for the development of hypothyroidism in
patients with type 1 diabetes and replacement with thyroid
hormones reduced the ﬂuctuations in blood glucose levels as
demonstrated by Leong et al. [43]. In a case control study
involving type 1 diabetic patients, those with subclinical
hypothyroidism experienced more frequent episodes of
hypoglycemia during the 12 months prior to the diagnosis
of hypothyroidism compared to euthyroid diabetics. On the
other hand, both clinical and subclinical hypothyroidisms
have been recognized as insulin resistant states [44–46]. In
vivo and in vitro studies have shown that this is due to
impaired insulin stimulated glucose utilization in peripheral
tissues [44, 45, 47, 48]. A recent study involving subjects
from a Chinese population found a higher TSH level in
patients with metabolic syndrome compared to that in the
nonmetabolic syndrome group suggesting that subclinical
hypothyroidism may be a risk factor for metabolic syndrome
[49]. More recently, Erdogan et al. found an increased
frequency of metabolic syndrome in subclinical and overt
hypothyroidism compared to healthy controls [50]. There-
fore, it seems prudent to consider hypothyroidism in newly
diagnosed metabolic syndrome patients. This raises the issue
whether routine screening for thyroid disease in all patients
newly diagnosed with metabolic syndrome will be cost
eﬀective. Furthermore, an increased risk of nephropathy was
shown in type 2 diabetic patients with subclinical hypothy-
roidism [51] which could be explained by the decrease in
cardiac output and increase in peripheral vascular resistance
seen with hypothyroidism and the resulting decrease in
renal ﬂow and glomerular ﬁltration rate [52]. In 2005,
Den Hollander et al. reported that treating hypothyroidism
improved renal function in diabetic patients [53]. As for
retinopathy, Yang et al. demonstrated recently that diabetic
patients with subclinical hypothyroidism have more severe
retinopathy than euthyroid patients with diabetes [54].
The increased risk of retinopathy and nephropathy
observed in diabetic patients with subclinical hypothy-
roidism provides evidence in favor of screening patients with
type 2 diabetes for thyroid dysfunction and treating when
present.
4.Leptin,Adiponectin,Ghrelin,and
Thyroid Hormones
Thyroid hormones may inﬂuence carbohydrate mechanisms
via its interaction with adipocytokines and gut hormones.
Among these adipocytokines, adiponectin is the most abun-
dant adipokine secreted by the adipose tissue and has impor-
tant insulin-sensitizing properties. Low levels of adiponectin
have been shown to confer a higher risk for development of
type 2 diabetes. Adiponectin and thyroid hormones share
some biological properties including reduction in body fat
by increasing thermogenesis and lipid oxidation [55]. It has
been suggested that adiponectin might inﬂuence thyroid
hormone production through its interaction with gC1q
receptor found in thyroid mitochondria [56]. On the other
hand, it was recently shown that T3 exhibited an inhibitory
eﬀect in rat models on adiponectin mRNA expression
particularly on white adipose tissue [57]. The relationship
between thyroid hormones and adiponectin remains to beJournal of Thyroid Research 3
clariﬁed and limited studies addressing this issue have shown
inconsistent results. Some studies found that adiponectin are
increased in hyperthyroidism [58–60], whereas other studies
report unchanged levels in states of excess thyroid hormones
[61, 62]. In hypothyroidism, reduced levels of adiponectin
have been shown by Dimitriadis et al. [44], and comparable
levels of adiponectin were observed in hypothyroid patients
and controls in a study by Nagasaki et al. [63]. Therefore, no
deﬁnite conclusion can yet be drawn, and further studies are
needed to clarify the above controversies.
Leptin is another hormone produced by adipocytes
that regulates energy expenditure and body weight. A
correlation between leptin and thyroid hormones has been
demonstrated in several studies. However, results have also
been discordant. Some studies showed a decrease in leptin
levels in hyperthyroidism [61, 64], whereas others observed
unchanged levels [65–67]. Similarly, increased [64, 67],
unchanged [66], and even decreased [65]v a l u e so fl e p t i n
have been reported in hypothyroid patients. An increase in
serum leptin and insulin have been described in hypothyroid
dogs [68]. On the other hand, leptin, by enhancing the
activity of type I iodothyronine 5 -deiodinase enzyme, could
result in an increase in circulating T3 level [69]. The changes
in fat mass accompanying thyroid diseases complicates the
interpretation of the results of studies on leptin and thy-
roid dysfunction. However, the complex interplay between
thyroid hormones and leptin and its possible inﬂuence on
carbohydrate metabolism remains to be elucidated.
Ghrelin is an orexigen secreted from the fundus of
the stomach. It has been shown to exert several diabeto-
genic eﬀects including decreasing secretion of the insulin
sensitizing hormone adiponectin [70]. In addition, ghrelin
circulates in two diﬀerent forms acylated and desacylated
ghrelin with the latter constituting the major circulating
form. Ghrelin levels are lower in obese subjects and those
with type 2 diabetes, states associated with hyperinsulinemia
[71]. Reduced ghrelin levels were observed in hyperthyroid
patients [72, 73], and these levels rose to normal values after
pharmacological treatment of hyperthyroidism [74–76].
Hyperthyroidism, being a state of negative energy balance
should result in an increase in ghrelin levels. Interestingly,
ghrelin levels in thyroid dysfunction states seem to correlate
with insulin resistance rather than food intake and energy
balance [77]. Hyperthyroidism is associated with insulin
resistance [77] and hyperinsulinemia suppresses ghrelin
levels [78]. Increased levels of ghrelin has been observed in
hypothyroid patients, and these levels normalized with L-
thyroxine treatment [74, 79].
In hypothyroid rat models, increased circulating ghrelin
and gastric ghrelin mRNA levels were demonstrated by
Caminos et al. [80]. However, in other studies, hypothyroid
patients were reported to have comparable ghrelin levels to
thatofhealthysubjectsandthoselevelswerenotsigniﬁcantly
altered after thyroid hormone replacement [77, 81, 82].
Therefore, the limited number of studies assessing the link
between thyroid dysfunction, on one hand, and ghrelin
and adipokines, on the other hand, have yielded conﬂicting
results.Thesediscrepanciescouldbepotentiallyexplainedby
diﬀerences in individuals’ characteristics, changes in fat mass
and energy expenditure accompanying hyper- or hypothy-
roidism, duration and degree of thyroid dysfunction, and
variability in the assays used for hormonal measurements
particularly for ghrelin. As previously mentioned, ghrelin
circulates in two major forms, acyl ghrelin which exerts a
stimulatory eﬀect on food intake and desacyl ghrelin which
reduces food intake inducing a state of negative energy
balance. Measuring either form or measuring total ghrelin
will lead to confounding results.
5. Thyroid Functionand EnergyExpenditure
Besides all of the above described mechanisms, thyroid
hormones can indirectly aﬀect glucose metabolism through
modulation of energy homeostasis. Although the underlying
mechanisms have not yet been clearly deﬁned, thyroid
hormones have been shown to alter the expression of
uncoupling proteins in brown adipose tissue involved in
eﬀective thermoregulation [83].
More recently, a role for thyroid hormones and TRH
in the central regulatory pathways for thermogenesis has
been identiﬁed. TRH neurons in the hypothalamus express
both thyroid hormone nuclear receptors (TRs) and type
4 melanocortin receptor (MC4R), a key receptor involved
in central energy regulation [84]. Activation of MC4R
reduces food intake and increases energy expenditure and
inactivating mutations in MC4R are associated with obesity
[85]. The repressive eﬀect of T3 on the expression of MC4R
helps in conserving energy in hyperthyroid states [86].
Furthermore, both the POMC (pro) and AgRP (Agouti-
related protein) neurons of the arcuate nucleus act at the
MC4R. Thus, T3, by reducing the expression of MC4R, has
been shown to decrease the hypothalamic sensitivity of the
POMC and AgRP signaling [86].
AMP-activated protein kinase (AMPK), a cellular energy
sensor, mediates the eﬀects of various nutritional and
hormonal signals in the hypothalamus.
Mice lacking AMPKα2 in POMC neurons developed
obesity due to a reduced resting metabolite rate and a
defective nutrient handling. On the other hand, AMPKα2
knockout mice in AgRP neurons remained lean with an
enhanced sensitivity to melanocortin agonists [87]. On
the other hand, injecting an adenovirus expressing the
dominant-negative form of AMPK (Ad-DN AMPK) into the
hypothalamus of male rats resulted in signiﬁcant decrements
in glucose production. Recently, L´ opez et al. showed that
hyperthyroidism or central administration of T3 reduced the
activity of hypothalamic AMPK [88]. Consequently, thyroid
hormones could indirectly alter glucose metabolism via their
interaction with various hypothalamic signals. However, the
exact mechanisms behind this complex interaction remains
to be clariﬁed.
6.EffectsofDiabetesMellitusonThyroid
Hormones and Thyroid Diseases
Altered thyroid hormones have been described in patients
with diabetes especially those with poor glycemic control.
In diabetic patients, the nocturnal TSH peak is blunted4 Journal of Thyroid Research
or abolished, and the TSH response to TRH is impaired
[89] .R e d u c e dT 3l e v e l sh a v eb e e no b s e r v e di nu n c o n t r o l l e d
diabetic patients. This “low T3 state” could be explained
by an impairment in peripheral conversion of T4 to T3
that normalizes with improvement in glycemic control.
However, in a study by Coiro et al. involving type 1
diabetes patients with absent residual pancreatic beta cell
function, an amelioration in glycemic control did not restore
the normal nocturnal TSH peak suggesting a diabetes-
dependent alteration in the central control of TSH [90].
Higher levels of circulating insulin associated with insulin
resistance have shown a proliferative eﬀect on thyroid tissue
resulting in larger thyroid size with increased formation of
nodules [91, 92]. A higher prevalence of type 1 diabetes
is observed in patients with Grave’s orbitopathy than in
the normal population. Furthermore, the vasculopathic
changes associated with diabetes renders the optic nerve
more susceptible to the pressure exerted by the enlarged
extraocular muscles. Consequently, a higher incidence of
dysthyroid optic neuropathy is observed in diabetic sub-
jects with Graves ophthalmopathy compared to nondiabetic
[93].
7. Conclusion
The relationship between thyroid disorders and diabetes
mellitus is characterized by a complex interdependent
interaction. Insulin resistance states may increase thyroid
gland nodularity and coexisting diabetes may increase risk of
visual loss in patients with Graves’ disease. Hyperthyroidism
impairs glycemic control in diabetic subjects, while hypothy-
roidism may increase susceptibility to hypoglycemias thus
complicating diabetes management. Additionally, thyroid
hormones may further alter carbohydrate metabolism via
its interaction with leptin, adiponectin, and gut hormones,
namely, ghrelin. However, this association and the resulting
alteration in metabolic eﬀects need further research. It has
been shown that thyroid dysfunctions are more prevalent
in people with diabetes and particularly type 1 diabetes.
Furthermore, it seems that unidentiﬁed thyroid dysfunction
could negatively impact diabetes and its complications.
A higher frequency of retinopathy and nephropathy was
observed in diabetic patients with subclinical hypothy-
roidism, and more severe retinopathy was noted as well.
Therefore, management of subclinical hypothyroidism in
patientswithdiabetesmayprovebeneﬁcial.Weconcludethat
a systematic approach to thyroid testing in diabetic subjects
is favorable; however, no deﬁnitive guidelines exist regard-
ing screening for thyroid dysfunction in diabetic patients.
Finally, whether all patients with diabetes should be screened
for thyroid function or whether patients with subclinical
thyroid disease should be treated merits reconsideration.
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